Polymeric drug-delivery systems: Role in P-gp efflux system inhibition

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 32, Issue 3, 2015, Pages 247-275

  Gupta, Preeti ^a   Garg, Tarun ^a   Tanmay, M ^a   Arora, Saahil ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

ABC transporter; Chemotherapy; Multidrug resistance; P gp efflux pump modulators; Polymeric drug delivery

Indexed keywords

AMPRENAVIR; BUNITROLOL; CARBAMAZEPINE; CELIPROLOL; CIMETIDINE; CISPLATIN; CORTICOSTERONE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIGITOXIN; DILTIAZEM; DOCETAXEL; DOMPERIDONE; DRUG CARRIER; GREPAFLOXACIN; LOPERAMIDE; NELFINAVIR; PACLITAXEL; PERMEABILITY GLYCOPROTEIN EFFLUX PUMP INHIBITOR; PHENYTOIN; PHOSPHATIDYLSERINE; PROTEIN INHIBITOR; RANITIDINE; SURFACTANT; TACROLIMUS; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; DRUG; MULTIDRUG RESISTANCE PROTEIN; POLYMER;

ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; CANCER CELL LINE; CELL MEMBRANE PERMEABILITY; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; EFFLUX RATE CONSTANT; ENZYME SUBSTRATE COMPLEX; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHEMISTRY; HUMAN; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84949514054     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2015011592     Document Type: Review

References (183)

1. Kaur R, Garg T, Malik B, Gupta UD, Gupta P, Rath G, Goyal AK. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv. 2014:1-6. doi:10.3109/10717544.2014.920428.
2. Kaur M, Malik B, Garg T, Rath G, Goyal AK. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv. 2014. doi:10.3109/10717544.2014.920428.
3. Chaudhary S, Garg T, Murthy RS, Rath G, Goyal AK. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target. 2014;22(10):871-82.
4. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Dev Rev. 1999;36(2):179-94.
5. Fortuna A, Alves G, Falcão A. In vitro and in vivo relevance of the P-glycoprotein probe substrates in drug discovery and development: Focus on Rhodamine 123, digoxin and talinolol. J Bioequiv Avail. 2011;01(02). doi:10.4172/jbb.S2-001.
6. Srivalli KMR, Lakshmi P. Overview of P-glycoprotein inhibitors: A rational outlook. Braz J Pharm Sci. 2012;48(3):353-67.
7. Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014;53:10-6.
8. Garg T. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 2014:1-8. doi:10.3109/21691401.2014.916715.
9. Garg T, Goyal AK. Iontophoresis: Drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett. 2012;2(4):270-80.
10. Garg T, Goyal AK. Liposomes: Targeted and controlled delivery system. Drug Deliv Lett. 2014;4(1):62-71.
11. Garg T, Goyal AK. Medicated chewing gum: Patient compliance oral drug delivery system. Drug Deliv Lett. 2014;4(1):72-8.
12. Garg T, Goyal AK. Biomaterial-based scaffolds: Current status and future directions. Expert Opin Drug Deliv. 2014;11(5):767-89.
13. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 2014;31(1):49-88.
14. Garg T, Goyal AK, Arora S, Murthy R. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug Deliv Lett. 2012;2(4):251-61.
15. Bernkop-Schnürch A, Grabovac V. Polymeric efflux pump inhibitors in oral drug delivery. Am J Drug Delivery. 2006;4(4):263-72.
16. Garg T, Kumar A, Rath G, Goyal AK. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Crit Rev Ther Drug Carrier Syst. 2014;31(6):531-57.
17. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem. 1993;62(1):385-427.
18. Hrycyna CA, Airan LE, Germann UA, Ambudkar SV, Pastan I, Gottesman MM. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry. 1998;37(39):13660-73.
19. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. 2014. Cited in PubMed: PMID 24456019.
20. Kataria K, Sharma A, Garg T, Goyal AK, Rath G. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Lett. 2014;4(1):79-86.
21. Tombline G, Bartholomew L, Gimi K, Tyndall GA, Senior AE. Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis. J Biol Chem. 2004;279(7):5363-73.
22. Garg T, Rath G, Goyal AK. Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease, psoriasis. Crit Rev Ther Drug Carrier Syst. 2014;31(4):331-64.
23. Kimura Y, Matsuo M, Takahashi K, Saeki T, Kioka N, Amachi T, Ueda K. ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein. Curr Drug Metab. 2004;5(1):1-10.
24. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv. 2013. Cited in PubMed: PMID 24251352.
25. Garg T, Singh O, Arora S, Murthy R. Dendrimer: A novel scaffold for drug delivery. Int J Pharm Sci Rev Res. 2011;7(2):211-20.
26. Tandon VR, Kapoor B, Bano G, Gupta S, Gillani Z, Kour D. P-glycoprotein: Pharmacological relevance. Ind J Pharm. 2006;38(1):13-24.
27. Garg T, Singh O, Arora S, Murthy R. Patented microencapsulation techniques and its application. J Pharm Res. 2011;4(7):2097-102.
28. Garg T, Singh O, Arora S, Murthy R. Scaffold: A novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012;29(1):1-63.
29. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharm Toxicol. 1999;39:361-98.
30. Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci. 2006;27(5):392-400.
31. Kaur VP, Goyal S, Kaur A, Kaur A, RSR M. Thiolated chitosan: An efficient polymer for intranasal drug delivery. Int J Pharm Photon. 2013;104:283-301.
32. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: An excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 2013;30(5):369-409.
33. Goyal AK, Rath G, Garg T. Nanotechnological approaches for genetic immunization. In: Erdman VA, Barciszewski. DNA and RNA nanobiotechnologies in medicine: Diagnosis and treatment of diseases. Berlin: Springer; 2013. pp. 67-120.
34. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst. 2014;31(2):89-119.
35. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for treating glaucoma. Crit Rev Ther Drug Carrier Syst. 2014;31(5):365-405.
36. Hussain T, Garg T, Goyal AK, Rath G. Biomedical applications of nanofiber scaffolds in tissue engineering. J Biomater Tissue Eng. 2014;4(8):600-23.
37. Johal HS, Garg T, Rath G, Goyal AK. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 2014:1-14. Cited in PubMed: PMID 24959937.
38. Beaulieu E, Demeule M, Ghitescu L, Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J. 1997;326(Pt 2):539-44.
39. Joly B, Fardel O, Cecchelli R, Chesne C, Puozzo C, Guillouzo A. Selective drug transport and P-glycoprotein activity in an in vitro blood-brain barrier model. Toxicol In Vitro. 1995;9(4):357-64.
40. Ramakrishnan P. The role of P-glycoprotein in the blood-brain barrier. Einstein Quart J Biol Med. 2003;19:160-5.
41. Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 2009;12(1):46-78.
42. Saito T, Zhang ZJ, Tsuzuki H, Ohtsubo T, Yamada T, Yamamoto T, Saito H. Expression of P-glycoprotein in inner ear capillary endothelial cells of the guinea pig with special reference to blood-inner ear barrier. Brain Res. 1997;767(2):388-92.
43. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci. 1988;85(12):4350-4.
44. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev. 2003;55(1):125-32.
45. Melaine N, Liénard MO, Dorval I, Le Goascogne C, Lejeune H, Jégou B. Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol Reprod. 2002;67(6):1699-707.
46. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta-Biom. 1976;455(1):152-62.
47. Joshi D, Garg T, Goyal AK, Rath G. Advanced drug delivery approaches against periodontitis. Drug Deliv. 2014:1-15. Cited in PubMed: PMID 25005586.
48. Kalia V, Garg T, Rath G, Goyal AK. Development and evaluation of a sublingual film of the antiemetic granisetron hydrochloride. Artif Cells Nanomed Biotechnol. 2014:1-5. doi: 10.3109/21691401.2014.984303.
49. Kaur M, Garg T, Narang RK. A review of emerging trends in the treatment of tuberculosis. Artif Cells Nanomed Biotechnol. 2014:1-7. doi: 10.3109/21691401.2014.962745.
50. Kaur N, Garg T, Goyal AK, Rath G. Formulation, optimization and evaluation of curcumin-β-cyclodextrin-loaded sponge for effective drug delivery in thermal burns chemotherapy. Drug Deliv. 2014:1-10. Cited in PubMed: PMID 25268151.
51. Kaur P, Garg T, Rath G, Murthy RS, Goyal AK. Surfactant-based drug delivery systems for treating drug-resistant lung cancer. Drug Deliv. 2014:1-12. Cited in PubMed: PMID 25013959.
52. Kaur R, Garg T, Rath G, Goyal AK. Advanced aerosol delivery devices for potential cure of acute and chronic diseases. Crit Rev Ther Drug Carrier Syst. 2014;31(6):495-530.
53. Kaur V, Garg T, Rath G, Goyal AK. Therapeutic potential of nanocarrier for overcoming to P-glycoprotein. J Drug Target. 2014;22(10):859-70.
54. Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: Targeted gastro-retentive drug delivery systems. J Drug Target. 2015;23(2):109-24.
55. Pabreja S, Garg T, Rath G, Goyal AK. Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes. Artif Cells Nanomed Biotechnol. 2014:1-8. Cited in PubMed: PMID 25307269.
56. Rohilla R, Garg T, Bariwal J, Goyal AK, Rath G. Development, optimization and characterization of glycyrrhetinic acid-chitosan nanoparticles of atorvastatin for liver targeting. Drug Deliv. 2014:1-8. Cited in PubMed: PMID 25379806.
57. Singh K, Arora N, Garg T. RFID: A trustable security tool in pharmaceutical industry. Am J Pharm Tech Res. 2012;2(2):113-27.
58. Singh K, Arora N, Garg T. Superbug: Antimicrobial resistance due to NDM-1. Int J Inst Pharm Life Sci. 2012;2(2):58-66.
59. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. Transmucosal delivery of docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol. 2014. Cited in PubMed: PMID 24621011.
60. Rohilla R, Garg T, Goyal AK, Rath G. Herbal and polymeric approaches for liver-targeting drug delivery: Novel strategies and their significance. Drug Deliv. 2014:1-17. Cited in PubMed: PMID 25101832.
61. Singh O, Garg T, Rath G, Goyal AK. Microbicides for the treatment of sexually transmitted HIV infections. J Pharm. 2014;(2014):1-18.
62. Sharma A, Garg T, Aman A, Panchal K, Sharma R, Kumar S, Markandeywar T. Nanogel: An advanced drug delivery tool: Current and future. Artif Cells Nanomed Biotechnol. 2014:1-13. Cited in PubMed: PMID 25053442.
63. Sharma R, Singh H, Joshi M, Sharma A, Garg T, Goyal AK, Rath G. Recent advances in polymeric electrospun nanofibers for drug delivery. Crit Rev Ther Drug Carrier Syst. 2014;31(3):187-217.
64. Sharma R, Garg T, Goyal AK, Rath G. Development, optimization and evaluation of polymeric electrospun nanofiber: A tool for local delivery of fluconazole for management of vaginal candidiasis. Artif Cells Nanomed Biotechnol. 2014:1-8. Cited in PubMed: PMID 25315503.
65. Singh B, Garg T, Goyal AK, Rath G. Recent advancements in the cardiovascular drug carriers. Artif Cells Nanomed Biotechnol. 2014:1-10. Cited in PubMed: PMID 25046615.
66. De Graaf D, Sharma RC, Mechetner EB, Schimke RT, Roninson IB. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci. 1996;93(3):1238-42.
67. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 2014:1-15. Cited in PubMed: PMID 25006687.
68. Modgill V, Garg T, Goyal AK, Rath G. Permeability study of ciprofloxacin from ultra-thin nanofibrous film through various mucosal membranes. Artif Cells Nanomed Biotechnol. 2014:1-6. Cited in PubMed: PMID 24915047.
69. Morie A, Garg T, Goyal AK, Rath G. Nanofibers as novel drug carrier: An overview. Artif Cells Nanomed Biotechnol. 2014:1-9. Cited in PubMed: PMID 25016918.
70. Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Dis Today. 2009;14(21):1067-74.
71. Padowski JM, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. In: Zhou J, editor. Multi-drug resistance in cancer. Berlin: Springer; 2010. pp. 359-84.
72. Sreenivas S, Pai K. Thiolated chitosans: Novel polymers for mucoadhesive drug delivery-a review. Trop J Pharm Res. 2008;7(3):1077-88.
73. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharm. 2003;42(1):59-98.
74. Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Comm. 1988;153(3):959-66.
75. Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol Pharm Bull. 1998;21(10):1062-6.
76. Chen C, Liu X, Smith BJ. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Met. 2003;4(4):272-91.
77. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41(5):1967-72.
78. Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bio Chem. 1996;7(2):209-16.
79. Friche E, Jensen P, Sehested M, Demant E, Nissen N. The solvents cremophor EL and Tween 80 modulate Daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 1989;2(9):297-303.
80. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2- mediated drug efflux. Br J Pharm. 2004;143(7):856-64.
81. Jodoin J, Demeule M, Béliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta-Mol Cell Res. 2002;1542(1):149-59.
82. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 1997;57(23): 5246-53.
83. Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): A new approach in breast cancer therapy. Exp Opin Pharm. 2002;3(12):1739-51.
84. Mohrbacher AF, Gregory SA, Gabriel DA, Rusk JM, Giles FJ. Liposomal Daunorubicin (DaunoXome) plus Dexamethasone for patients with multiple myeloma. Cancer. 2002;94(10):2645-52.
85. Oudard S, Thierry A, Jorgensen TJ, Rahman A. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chem Pharm. 1991;28(4):259-65.
86. Thierry A, Vige D, Coughlin S, Belli J, Dritschilo A, Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 1993;7(6):572-9.
87. Jain AK, Swarnakar NK, Das M, Godugu C, Singh RP, Rao PR, Jain S. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model. Mol Pharm. 2011;8(4):1140-51.
88. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett. 2005;156(3):319-29.
89. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: Challenges and opportunities. J Contr Rel. 2013;170(1):15-40.
90. Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today. 2009;14(21-22):1067-74.
91. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, Shim CK, Kim DD. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Contr Rel. 2009;140(2):86-94.
92. Carreno-Gomez B, Duncan R. Compositions with enhanced oral bioavailability. 2002. U.S. Patent 20030211072.
93. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci. 2002;91(9):1991-2002.
94. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharmsci. 2002;4(4):193-205.
95. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs. III: Formulation using drug delivery systems. Drug Discov Today. 2013;18(1):99-104.
96. Shen Q, Lin Y, Handa T, Doi M, Sugie M, Wakayama K, Okada N, Fujita T, Yamamoto A. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm. 2006;313(1):49-56.
97. Föger F, Hoyer H, Kafedjiiski K, Thaurer M, Bernkop-Schnürch A. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials. 2006;27(34):5855-60.
98. Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N, Fujita T, Yamamoto A. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci. 2004;93(4):877-85.
99. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25(4):445-53.
100. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002;54(5):759-79.
101. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Contr Rel. 2004;95(3):447-53.
102. Greindl M, Foger F, Hombach J, Bernkop-Schnurch A. In vivo evaluation of thiolated poly(acrylic acid) as a drug absorption modulator for MRP2 efflux pump substrates. Eur J Pharm Biopharm. 2009;72(3):561-6.
103. Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Contr Rel. 2006;111(1-2):41-6.
104. Koukourakis M, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N. High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours. Br J Cancer. 2000;83(10):1281.
105. Nassar T, Rom A, Nyska A, Benita S. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J Contr Rel. 2009;133(1):77-84.
106. Lian H, Zhang T, Sun J, Liu X, Ren G, Kou L, Zhang Y, Han X, Ding W, Ai X. Enhanced oral delivery of paclitaxel using acetylcysteine functionalized chitosan-vitamin E succinate nanomicelles based on a mucus bioadhesion and penetration mechanism. Mol Pharm. 2013;10(9):3447-58.
107. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res. 2004;21(2):261-70.
108. Nokihara H, Yano S, Sone S. Overcoming of multidrug resistance by anti-P-glycoprotein monoclonal antibody. Nih Rin Japan J Clin Med. 1997;55(5):1128-34.
109. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. 2014;42(6):406-12.
110. Lo YL. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Contr Rel. 2003;90(1):37-48.
111. Hoffmann S, Winkler U. Neutral and zwitterionic detergents: Dependence of biological effectiveness on critical micellar concentration. Schrift Ver fur Wasser Boden Lufth. 1991;89:679-87.
112. Prakash AS. Selecting surfactants for the maximum inhibition of the activity of the multidrug resistance efflux pump transporter, P-glycoprotein: Conceptual development. J Excip Food Chem. 2010;1(3):51-9.
113. Collnot EM, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, Schaefer UF, Lehr CM. Influence of vitamin E TPGS poly (ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Contr Rel. 2006;111(1):35-40.
114. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999;16(10):1550-6.
115. Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: Influence on ATPase activity and membrane fluidity. Mol Pharm. 2007;4(3):465-74.
116. Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. Vitamin E TPGS P-glycoprotein inhibition mechanism: Influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm. 2010;7(3):642-51.
117. Anbharasi V, Cao N, Feng SS. Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res Part A. 2010;94(3):730-43.
118. Wang Y, Guo M, Lu Y, Ding LY, Ron WT, Liu YQ, Song FF, Yu SQ. α-Tocopheryl polyethylene glycol succinate-emulsified poly (lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnol. 2012;23(49):495103.
119. Parsa A, Saadati R, Abbasian Z, Aramaki SA, Dadashzadeh S. Enhanced permeability of etoposide across everted sacs of rat small intestine by vitamin E-TPGS. Ir J Pharm Res. 2013;12(Suppl):37.
120. Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Ar Pharm Res. 2003;26(9):768-72.
121. Zhu S, Huang R, Hong M, Jiang Y, Hu Z, Liu C, Pei Y. Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. Eur J Pharm Sci. 2009;37(5):573-80.
122. Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res. 2004;21(12):2226-33.
123. Slepnev VI, Kuznetsova LE, Gubin AN, Batrakova EV, Alakhov V, Kabanov AV. Micelles of poly(oxyethylene)-poly(oxypropylene) block copolymer (pluronic) as a tool for low-molecular compound delivery into a cell: Phosphorylation of intracellular proteins with micelle incorporated [γ-32P]ATP. Biochem Int. 1992;26(4):587-95.
124. Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharm Exp Ther. 2003;304(2):845-54.
125. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies. J Pharm Exp Ther. 2001;296(2):551-7.
126. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer. 2000;83(3):366-74.
127. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization. J Pharm Exp Ther. 2001;299(2):483-93.
128. Bromberg L. Polymeric micelles in oral chemotherapy. J Contr Rel. 2008;128(2):99-112.
129. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Met Dis. 2007;35(7):1142-8.
130. Shaik N, Giri N, Elmquist WF. Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: Cell accumulation and equilibrium dialysis studies. J Pharm Sci. 2009;98(11):4170-90.
131. Guan Y, Huang J, Zuo L, Xu J, Si L, Qiu J, Li G. Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. Ar Pharm Res. 2011;34(10):1719-28.
132. Zhao Y, Li Y, Ge J, Li N, Li LB. Pluronic-poly (acrylic acid)-cysteine/Pluronic L121 mixed micelles improve the oral bioavailability of paclitaxel. Drug Dev Industl Pharm. 2013(0):1-11.
133. Wei Z, Yuan S, Hao J, Fang X. Mechanism of inhibition of P-glycoprotein mediated efflux by pluronic P123/F127 block copolymers: Relationship between copolymer concentration and inhibitory activity. Eur J Pharm Biopharm. 2013;83(2):266-74.
134. Siddiquia N, Alia R, Alama S, Ahsana W. Pharmacological profile of benzoxazines: a short review. J Chem Pharm Res. 2010;2(4):309-10.
135. Roldo M, Hornof M, Caliceti P, Bernkop-Schnürch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: Synthesis and in vitro evaluation. Eur J Pharm Biopharm. 2004;57(1):115-21.
136. Srinivas NR. Dual drug interactions via P-glycoprotein (P-gp)/cytochrome P450 (CYP3A4) interplay: Recent case study of oral atorvastatin and verapamil. Eur J Clin Pharm. 2008;64(11):1135-6.
137. Clausen AE, Kast CE, Bernkop-Schnürch A. The role of glutathione in the permeation enhancing effect of thiolated polymers. Pharm Res. 2002;19(5):602-8.
138. Kast CE, Guggi D, Langoth N, Bernkop-Schnürch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res. 2003;20(6):931-6.
139. Föger F, Kafedjiiski K, Hoyer H, Loretz B, Bernkop-Schnürch A. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. J Drug Target. 2007;15(2):132-9.
140. Palmberger TF, Hombach J, Bernkop-Schnürch A. Thiolated chitosan: Development and in vitro evaluation of an oral delivery system for acyclovir. Int J Pharm. 2008;348(1):54-60.
141. Föger F, Malaivijitnond S, Wannaprasert T, Huck C, Bernkop-Schnürch A, Werle M. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats. J Drug Target. 2008;16(2): 149-55.
142. Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnürch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Contr Rel. 2010;147(1):62-9.
143. Jiang L, Li X, Liu L, Zhang Q. Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer. Nanoscale Res Lett. 2013;8(1):1-11.
144. Hauptstein S, Bonengel S, Griessinger J, Bernkop-Schnürch A. Synthesis and characterization of pH tolerant and mucoadhesive (thiol-polyethylene glycol) chitosan graft polymer for drug delivery. J Pharm Sci. 2014;103(2):594-601.
145. Gradauer K, Barthelmes J, Vonach C, Almer G, Mangge H, Teubl B, Roblegg E, Dünnhaupt S, Fröhlich E, Bernkop-Schnürch A. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J Contr Rel. 2013;172(3):872-8.
146. Trapani A, Palazzo C, Contino M, Perrone MG, Cioffi N, Ditaranto N, Colabufo NA, Conese M, Trapani G, Puglisi G. Mucoadhesive properties and interaction with P-glycoprotein (P-gp) of thiolated-chitosans and -glycol chitosans and corresponding parent polymers: A comparative study. Biomacromolecules. 2014;15(3):882-93.
147. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 2004;278(1):119-31.
148. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-8.
149. Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2013;65(6):880-90.
150. Ashiru-Oredope DA, Patel N, Forbes B, Patel R, Basit AW. The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. Int J Pharm. 2011;409(1):164-8.
151. Hugger ED, Audus KL, Borchardt RT. Effects of poly (ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci. 2002;91(9):1980-90.
152. Wang J, Qu H, Jin L, Zeng W, Qin L, Zhang F, Wei X, Lu W, Zhang C, Liang W. PEGylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J Pharm Sci. 2011;100(6):2267-77.
153. Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of PEGylated paclitaxel prodrug for oral delivery in rats. Int J Pharm. 2004;280(1):221-7.
154. Elamanchili P, McEachern C, Burt H. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J Pharm Sci. 2009;98(3):945-58.
155. Tan BJ, Liu Y, Chang KL, Lim B, Chiu G. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomed. 2011;7:651-61.
156. Zabaleta V, Ponchel G, Salman H, Agüeros M, Vauthier C, Irache JM. Oral administration of paclitaxel with PEGylated poly (anhydride) nanoparticles: Permeability and pharmacokinetic study. Eur J Pharm Biopharm. 2012;81(3):514-23.
157. Cambon A, Rey-Rico A, Barbosa S, Soltero J, Yeates S, Brea J, Loza M, Alvarez-Lorenzo C, Concheiro A, Taboada P. Poly (styrene oxide)-poly (ethylene oxide) block copolymers: From "classical" chemotherapeutic nanocarriers to active cell-response inducers. J Contr Rel. 2013;167(1):68-75.
158. El-Sayed M, Rhodes C, Ginski M, Ghandehari H. Transport mechanism (s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm. 2003;265(1):151-7.
159. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Advanced Drug Deliv Rev. 2005;57(15): 2147-62.
160. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-Propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Contr Rel. 2004;95(3):447-53.
161. Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, Oberlies NH, Manikumar G, Wani MC, Grinstaff MW. Dendrimer-encapsulated camptothecins: Increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 2006;66(24):11913-21.
162. Ke W, Zhao Y, Huang R, Jiang C, Pei Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci. 2008;97(6):2208-16.
163. Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly (amidoamine) dendrimers. Pharm Res. 2008;25(7):1723-9.
164. Lin Y, Fujimori T, Kawaguchi N, Tsujimoto Y, Nishimi M, Dong Z, Katsumi H, Sakane T, Yamamoto A. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J Contr Rel. 2011;149(1):21-8.
165. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery. Adv Drug Deliv Rev. 2012;64(6):571-88.
166. Liu Y, Chiu GN. Dual-functionalized PAMAM dendrimers with improved P-glycoprotein inhibition and tight junction modulating effect. Biomacromolecules. 2013;14(12):4226-35.
167. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136-51.
168. Hu FQ, Liu LN, Du YZ, Yuan H. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials. 2009;30(36):6955-63.
169. Gu YJ, Cheng J, Man CWY, Wong WT, Cheng SH. Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomed Nanotech Biol Med. 2012;8(2):204-11.
170. Cao N, Feng SS. Doxorubicin conjugated to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): Conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials. 2008;29(28):3856-65.
171. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, Greenberger LM, Horak ID. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008;14(6):1888-96.
172. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12(5):1606-14.
173. Singer JW, Shaffer S, Baker B, Bernareggi A, Stromatt S, Nienstedt D, Besman M. Paclitaxel poliglumex (XYOTAX; CT-2103): An intracellularly targeted taxane. Anti-Cancer Drugs. 2005;16(3):243-54.
174. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. 2005;48(11):3729-35.
175. Emilienne Soma C, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials. 2000;21(1):1-7.
176. Iqbal J, Sarti F, Perera G, Bernkop-Schnürch A. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials. 2011;32(1):170-5.
177. Föger F, Schmitz T, Bernkop-Schnürch A. In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials. 2006;27(23):4250-5.
178. Sarti F, Müller C, Iqbal J, Perera G, Laffleur F, Bernkop-Schnürch A. Development and in vivo evaluation of an oral vitamin B12 delivery system. Eur J Pharm Biopharm. 2013;84(1):132-7.
179. Mo R, Jin X, Li N, Ju C, Sun M, Zhang C, Ping Q. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials. 2011;32(20):4609-20.
180. Zambito Y, Fogli S, Zaino C, Stefanelli F, Breschi MC, Di Colo G. Synthesis, characterization and evaluation of thiolated quaternary ammonium-chitosan conjugates for enhanced intestinal drug permeation. Eur J Pharm Sci. 2009;38(2):112-20.
181. Gradauer K, Dünnhaupt S, Vonach C, Szöllösi H, Pali-Schöll I, Mangge H, Jensen-Jarolim E, Bernkop-Schnürch A, Prassl R. Thiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties. J Contr Rel. 2013;165(3):207-15.
182. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: Preparation, in vitro and ex vivo evaluation. Int J Nanomed. 2010;6:119-28.
183. Dünnhaupt S, Barthelmes J, Rahmat D, Leithner K, Thurner CC, Friedl H, Bernkop-Schnürch A. S-protected thiolated chitosan for oral delivery of hydrophilic macromolecules: Evaluation of permeation enhancing and efflux pump inhibitory properties. Mol Pharm. 2012;9(5):1331-41.